Modulating the Gut Microbiota Improves Glucose Tolerance, Lipoprotein Profile and Atherosclerotic Plaque Development in ApoE-Deficient Mice.

The importance of the gut microbiota (GM) in disease development has recently received increased attention, and numerous approaches have been made to better understand this important interplay. For example, metabolites derived from the GM have been shown to promote atherosclerosis, the underlying ca...

Full description

Bibliographic Details
Main Authors: Ida Rune, Bidda Rolin, Christian Larsen, Dennis Sandris Nielsen, Jenny E Kanter, Karin E Bornfeldt, Jens Lykkesfeldt, Karsten Buschard, Rikke Kaae Kirk, Berit Christoffersen, Johannes Josef Fels, Knud Josefsen, Pernille Kihl, Axel Kornerup Hansen
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4723129?pdf=render
_version_ 1818475366253068288
author Ida Rune
Bidda Rolin
Christian Larsen
Dennis Sandris Nielsen
Jenny E Kanter
Karin E Bornfeldt
Jens Lykkesfeldt
Karsten Buschard
Rikke Kaae Kirk
Berit Christoffersen
Johannes Josef Fels
Knud Josefsen
Pernille Kihl
Axel Kornerup Hansen
author_facet Ida Rune
Bidda Rolin
Christian Larsen
Dennis Sandris Nielsen
Jenny E Kanter
Karin E Bornfeldt
Jens Lykkesfeldt
Karsten Buschard
Rikke Kaae Kirk
Berit Christoffersen
Johannes Josef Fels
Knud Josefsen
Pernille Kihl
Axel Kornerup Hansen
author_sort Ida Rune
collection DOAJ
description The importance of the gut microbiota (GM) in disease development has recently received increased attention, and numerous approaches have been made to better understand this important interplay. For example, metabolites derived from the GM have been shown to promote atherosclerosis, the underlying cause of cardiovascular disease (CVD), and to increase CVD risk factors. Popular interest in the role of the intestine in a variety of disease states has now resulted in a significant proportion of individuals without coeliac disease switching to gluten-free diets. The effect of gluten-free diets on atherosclerosis and cardiovascular risk factors is largely unknown. We therefore investigated the effect of a gluten-free high-fat cholesterol-rich diet, as compared to the same diet in which the gluten peptide gliadin had been added back, on atherosclerosis and several cardiovascular risk factors in apolipoprotein E-deficient (Apoe-/-) mice. The gluten-free diet transiently altered GM composition in these mice, as compared to the gliadin-supplemented diet, but did not alter body weights, glucose tolerance, insulin levels, plasma lipids, or atherosclerosis. In parallel, other Apoe-/- mice fed the same diets were treated with ampicillin, a broad-spectrum antibiotic known to affect GM composition. Ampicillin-treatment had a marked and sustained effect on GM composition, as expected. Furthermore, although ampicillin-treated mice were slightly heavier than controls, ampicillin-treatment transiently improved glucose tolerance both in the absence or presence of gliadin, reduced plasma LDL and VLDL cholesterol levels, and reduced aortic atherosclerotic lesion area. These results demonstrate that a gluten-free diet does not seem to have beneficial effects on atherosclerosis or several CVD risk factors in this mouse model, but that sustained alteration of GM composition with a broad-spectrum antibiotic has beneficial effects on CVD risk factors and atherosclerosis. These findings support the concept that altering the microbiota might provide novel treatment strategies for CVD.
first_indexed 2024-12-10T09:11:38Z
format Article
id doaj.art-7e260d4bc6914d3d9feefa4dad2a5b9d
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-10T09:11:38Z
publishDate 2016-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-7e260d4bc6914d3d9feefa4dad2a5b9d2022-12-22T01:54:59ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01111e014643910.1371/journal.pone.0146439Modulating the Gut Microbiota Improves Glucose Tolerance, Lipoprotein Profile and Atherosclerotic Plaque Development in ApoE-Deficient Mice.Ida RuneBidda RolinChristian LarsenDennis Sandris NielsenJenny E KanterKarin E BornfeldtJens LykkesfeldtKarsten BuschardRikke Kaae KirkBerit ChristoffersenJohannes Josef FelsKnud JosefsenPernille KihlAxel Kornerup HansenThe importance of the gut microbiota (GM) in disease development has recently received increased attention, and numerous approaches have been made to better understand this important interplay. For example, metabolites derived from the GM have been shown to promote atherosclerosis, the underlying cause of cardiovascular disease (CVD), and to increase CVD risk factors. Popular interest in the role of the intestine in a variety of disease states has now resulted in a significant proportion of individuals without coeliac disease switching to gluten-free diets. The effect of gluten-free diets on atherosclerosis and cardiovascular risk factors is largely unknown. We therefore investigated the effect of a gluten-free high-fat cholesterol-rich diet, as compared to the same diet in which the gluten peptide gliadin had been added back, on atherosclerosis and several cardiovascular risk factors in apolipoprotein E-deficient (Apoe-/-) mice. The gluten-free diet transiently altered GM composition in these mice, as compared to the gliadin-supplemented diet, but did not alter body weights, glucose tolerance, insulin levels, plasma lipids, or atherosclerosis. In parallel, other Apoe-/- mice fed the same diets were treated with ampicillin, a broad-spectrum antibiotic known to affect GM composition. Ampicillin-treatment had a marked and sustained effect on GM composition, as expected. Furthermore, although ampicillin-treated mice were slightly heavier than controls, ampicillin-treatment transiently improved glucose tolerance both in the absence or presence of gliadin, reduced plasma LDL and VLDL cholesterol levels, and reduced aortic atherosclerotic lesion area. These results demonstrate that a gluten-free diet does not seem to have beneficial effects on atherosclerosis or several CVD risk factors in this mouse model, but that sustained alteration of GM composition with a broad-spectrum antibiotic has beneficial effects on CVD risk factors and atherosclerosis. These findings support the concept that altering the microbiota might provide novel treatment strategies for CVD.http://europepmc.org/articles/PMC4723129?pdf=render
spellingShingle Ida Rune
Bidda Rolin
Christian Larsen
Dennis Sandris Nielsen
Jenny E Kanter
Karin E Bornfeldt
Jens Lykkesfeldt
Karsten Buschard
Rikke Kaae Kirk
Berit Christoffersen
Johannes Josef Fels
Knud Josefsen
Pernille Kihl
Axel Kornerup Hansen
Modulating the Gut Microbiota Improves Glucose Tolerance, Lipoprotein Profile and Atherosclerotic Plaque Development in ApoE-Deficient Mice.
PLoS ONE
title Modulating the Gut Microbiota Improves Glucose Tolerance, Lipoprotein Profile and Atherosclerotic Plaque Development in ApoE-Deficient Mice.
title_full Modulating the Gut Microbiota Improves Glucose Tolerance, Lipoprotein Profile and Atherosclerotic Plaque Development in ApoE-Deficient Mice.
title_fullStr Modulating the Gut Microbiota Improves Glucose Tolerance, Lipoprotein Profile and Atherosclerotic Plaque Development in ApoE-Deficient Mice.
title_full_unstemmed Modulating the Gut Microbiota Improves Glucose Tolerance, Lipoprotein Profile and Atherosclerotic Plaque Development in ApoE-Deficient Mice.
title_short Modulating the Gut Microbiota Improves Glucose Tolerance, Lipoprotein Profile and Atherosclerotic Plaque Development in ApoE-Deficient Mice.
title_sort modulating the gut microbiota improves glucose tolerance lipoprotein profile and atherosclerotic plaque development in apoe deficient mice
url http://europepmc.org/articles/PMC4723129?pdf=render
work_keys_str_mv AT idarune modulatingthegutmicrobiotaimprovesglucosetolerancelipoproteinprofileandatheroscleroticplaquedevelopmentinapoedeficientmice
AT biddarolin modulatingthegutmicrobiotaimprovesglucosetolerancelipoproteinprofileandatheroscleroticplaquedevelopmentinapoedeficientmice
AT christianlarsen modulatingthegutmicrobiotaimprovesglucosetolerancelipoproteinprofileandatheroscleroticplaquedevelopmentinapoedeficientmice
AT dennissandrisnielsen modulatingthegutmicrobiotaimprovesglucosetolerancelipoproteinprofileandatheroscleroticplaquedevelopmentinapoedeficientmice
AT jennyekanter modulatingthegutmicrobiotaimprovesglucosetolerancelipoproteinprofileandatheroscleroticplaquedevelopmentinapoedeficientmice
AT karinebornfeldt modulatingthegutmicrobiotaimprovesglucosetolerancelipoproteinprofileandatheroscleroticplaquedevelopmentinapoedeficientmice
AT jenslykkesfeldt modulatingthegutmicrobiotaimprovesglucosetolerancelipoproteinprofileandatheroscleroticplaquedevelopmentinapoedeficientmice
AT karstenbuschard modulatingthegutmicrobiotaimprovesglucosetolerancelipoproteinprofileandatheroscleroticplaquedevelopmentinapoedeficientmice
AT rikkekaaekirk modulatingthegutmicrobiotaimprovesglucosetolerancelipoproteinprofileandatheroscleroticplaquedevelopmentinapoedeficientmice
AT beritchristoffersen modulatingthegutmicrobiotaimprovesglucosetolerancelipoproteinprofileandatheroscleroticplaquedevelopmentinapoedeficientmice
AT johannesjoseffels modulatingthegutmicrobiotaimprovesglucosetolerancelipoproteinprofileandatheroscleroticplaquedevelopmentinapoedeficientmice
AT knudjosefsen modulatingthegutmicrobiotaimprovesglucosetolerancelipoproteinprofileandatheroscleroticplaquedevelopmentinapoedeficientmice
AT pernillekihl modulatingthegutmicrobiotaimprovesglucosetolerancelipoproteinprofileandatheroscleroticplaquedevelopmentinapoedeficientmice
AT axelkorneruphansen modulatingthegutmicrobiotaimprovesglucosetolerancelipoproteinprofileandatheroscleroticplaquedevelopmentinapoedeficientmice